Search results
Is CRISPR Therapeutics Stock a Buy?
Motley Fool via Yahoo Finance· 4 hours agoCRISPR Therapeutics (NASDAQ: CRSP) is a star in the gene-editing therapy niche. The company made tremendous progress over the past few years, culminating...
Investors Heavily Search CRISPR Therapeutics AG (CRSP): Here is What You Need to Know
Zacks via Yahoo Finance· 4 days agoRecently, Zacks.com users have been paying close attention to CRISPR Therapeutics (CRSP). This makes...
CRISPR Therapeutics AG [CRSP] Records 200-Day SMA of $59.40 – Knox Daily
Knox Daily· 10 hours agoInvestors can speculate about the future of a stock by watching how its insiders buy and sell stocks. CRISPR Therapeutics AG shares valued at $1,173,232 were sold by Kulkarni ...
Is CRISPR Stock Going to $95? 1 Wall Street Analyst Thinks So.
Motley Fool via Yahoo Finance· 2 days agoCRISPR Therapeutics (NASDAQ: CRSP) closed last week down 8.5% after reporting first-quarter...
CRISPR can treat common form of inherited blindness, early data hint
LiveScience· 2 days agoA CRISPR therapy injected directly into the eye shows promise in treating the most common form of...
Gene Editing Breakthrough: CRISPR Improves Vision in Clinical Trial
SciTechDaily· 4 days agoMass Eye and Ear researchers say their findings support continued research and clinical trials of ...
CRISPR Therapeutics’ (CRSP) Neutral Rating Reiterated at Cantor Fitzgerald
ETF DAILY NEWS· 4 days agoCantor Fitzgerald reissued their neutral rating on shares of CRISPR Therapeutics (NASDAQ:CRSP – Free Report) in a research note issued to investors on Thursday, Benzinga reports ...
Five Best: Books on Breakthroughs in Biology
The Wall Street Journal· 21 hours agoDoudna and Samuel H. Sternberg (2017) 1. Changing the DNA code in a living organism—to correct a genetic disease, for example—was until recently...
CRISPR Therapeutics (NASDAQ:CRSP) Stock Price Down 2.1% After Analyst Downgrade
ETF DAILY NEWS· 7 days agoCRISPR Therapeutics AG (NASDAQ:CRSP – Get Free Report) shares dropped 2.1% during trading on Friday after Oppenheimer lowered their price target on the stock from $102.00 ...
Broker Revenue Forecasts For CRISPR Therapeutics AG (NASDAQ:CRSP) Are Surging Higher
Simply Wall St. via Yahoo Finance· 6 days agoCRISPR Therapeutics AG (NASDAQ:CRSP) shareholders will have a reason to smile today, with the...
